Jimin Health (603222.SH): Has not yet established a wellness center.

On January 10, Gelonghui reported that Jimin Health (603222.SH) stated on the interactive platform that its subsidiary, Ezhou South Hospital, has a rehabilitation department but has not established a health care center.

Gelonghui FinanceJan 10 15:53

Jimin Health (603222.SH): A subsidiary plans to accept relocation compensation.

On December 31, Gelonghui announced that Jimin Health (603222.SH) has completed the non-public issuance of Stocks fundraising for the "Annual Production of 850 Million Safe Syringes and Safe Injection Needle Technology Transformation Project". The office location of its wholly-owned subsidiary, Jumin Biotechnology Co., Ltd. (referred to as "Jumin Biotechnology"), has been relocated from "1888 Huhang Highway, Fengxian District, Shanghai" to "398 Renjie South Road, Fengxian, Shanghai". The "House Rental Agreement" between Jumin Biotechnology and its affiliate, Shanghai Shuangge Industrial Co., Ltd. (referred to as "Shanghai Shuangge Industrial"), has also been terminated. Given that:

Gelonghui FinanceDec 31, 2024 15:37

Jimin Health (603222.SH): Re-recognized as a high-tech enterprise.

On December 26, 2024, Ge Long Hui reported that Jimin Health (603222.SH) announced that based on the notice issued by the Office of the Leading Group for the Management of National High-Tech Enterprise Recognition, the company has once again passed the re-recognition as a high-tech enterprise. The certificate number is GR202433007778, with the issuance date on December 6, 2024, and a validity period of three years. This recognition as a high-tech enterprise is a re-recognition following the expiration of the company's original certificate.

Gelonghui FinanceDec 26, 2024 15:37

Chimin Health Management Signs 10-Year Manufacturing Deal

MT NewswiresDec 26, 2024 15:32

Express News | Jimin Health: Signed a 10-year manufacturing agreement with USA RTI Company.

BreakingsDec 19, 2024 16:01

Jimin Health (603222.SH): plans to be involved in the OEM production of safety injection needles and safety syringes and other products.

On December 19, Gelonghui announced that Jimin Health (603222.SH) has signed a "Manufacturing Agreement" with USA Retractable Technologies, Inc. (abbreviated as "RTI") for the subcontracted production of products such as safe injection needles and safe syringes. The company's wholly-owned subsidiary, Jumin Biotechnology Co., Ltd. (including its predecessor), has been the OEM manufacturer for safe injection needles and safe syringes for USA RTI since 2004, marking a cooperation of 20 years to date. This time

Gelonghui FinanceDec 19, 2024 16:01